We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.
No takes yet. Share an insight, caveat, or question.
Shields et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: